The total number of records retrieved from this search are 8. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_4656	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineCAL27	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.001 MOI	In-vitro result82% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4657	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineCAL27	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.005 MOI	In-vitro result42% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4658	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineCAL27	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.01 MOI	In-vitro result38% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4659	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineCAL27	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.05 MOI	In-vitro result30% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4660	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineCAL27	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.1 MOI	In-vitro result30% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4661	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineCAL27	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.5 MOI	In-vitro result30% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4662	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineCAL27	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration1 MOI	In-vitro result30% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4700	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneNo	Virus in combination with drug/radiationVirus combination with ATN-224 (8 micromolar/litre) an copper chelator show synergy	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineCAL27	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.5 MOI	In-vitro result42% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105